Prof. Hagit Eldar-Finkelman

Principle investigator of an active research laboratory at the Sackler School of Medicine at Tel Aviv University. Eldar-Finkelman's research is focused on the Signal Transduction field and drug development targeting protein kinases. A particular emphasis is given to the protein kinase GSK-3 a promising drug discovery target for neurodegenerative diseases. A substrate competitive inhibitor strategy (SCI strategy) is developed in the lab using computational and biochemical tools. This to achieve highly specific inhibitors for protein kinases.

ORCID: https://www.orcid.org/0000-0002-8460-9686/

Lab homepage: https://www.heflab.sites.tau.ac.il/